VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Avian pneumovirus DNA Vaccine expressing the F gene
Vaccine Information
  • Vaccine Name: Avian pneumovirus DNA Vaccine expressing the F gene
  • Target Pathogen: Avian pneumovirus
  • Target Disease: Turkey rhinotracheitis, Avian rhinotracheitis, Swollen head syndrome
  • Vaccine Ontology ID: VO_0004525
  • Type: DNA vaccine
  • Status: Research
  • Fusion protein gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pcDNA3.1 DNA vaccine plasmid
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Turkey Response

  • Vaccination Protocol: One-week-old SPF poults were arbitrarily separated into four groups of five or six birds. All vaccinations were delivered by syringe injection into the thigh muscle in 0.1-ml aliquots. Control birds received PBS at days 7 and 21 of age. Birds receiving either pCMV, pCMV-F, or pCMV-N received 50 ag of plasmid DNA on day 7 and 100 ag on day 21 (Kapczynski and Sellers, 2003).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Serum neutralizing antibodies were significantly higher in birds receiving pCMV-F compared with all other groups (Kapczynski and Sellers, 2003).
  • Challenge Protocol: Two weeks after the second vaccination, birds were challenged via intranasal route with 1 x 105 TCID50 Mn la per bird (Kapczynski and Sellers, 2003).
  • Efficacy: Poults receiving pCMV-F had significantly decreased levels of virus in tracheal swabs on all days in Experiment I and on day 7 in Experiment II compared with other groups. In addition, the percentage of birds displaying clinical signs of disease was decreased in turkeys receiving pCMV-F in both experiments. In experiments I and II, only 20% and 30%, respectively, of birds vaccinated with pCMV-F displayed clinical signs at day 7 (Kapczynski and Sellers, 2003).
References